nivazol: RN given refers to (17alpha)-isomer; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 9910575 |
CHEMBL ID | 2106806 |
CHEBI ID | 177683 |
SCHEMBL ID | 570242 |
MeSH ID | M0123563 |
Synonym |
---|
(1s,2r,13r,14s,17r,18s)-17-ethynyl-7-(4-luorophenyl)-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol |
CHEBI:177683 |
nivazol (usan) |
24358-76-7 |
D05194 |
nivacortol (inn) |
nivazol |
win-27914 |
CHEMBL2106806 |
unii-50u0z120rs |
nivazol [usan] |
nivacortolum [inn-latin] |
nivacortol |
nivacortolum |
win 27,914 |
2'-(p-fluorophenyl)-2'h-17alpha-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol |
2'h-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol, 2'-(4-fluorophenyl)-, (17alpha)- |
nivacortol [inn] |
50u0z120rs , |
einecs 246-202-4 |
2'h-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol, 2'-(4-fluorophenyl)-, (17.alpha.)- |
2'-(p-fluorophenyl)-2'h-17.alpha.-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol |
SCHEMBL570242 |
(1s,2r,13r,14s,17r,18s)-17-ethynyl-7-(4-fluorophenyl)-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol |
Q27260822 |
DTXSID301043242 |
Class | Description |
---|---|
steroid | Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (16.67%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |